Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnolo...
How will the results affect valuation metrics such as EV/EBITDA or price‑to‑earnings multiples for Stevanato?
What does the quarter’s cash conversion and free cash flow look like after the increased revenue and margins?
Are there any regional risks or opportunities highlighted by the performance, particularly regarding European versus U.S. markets?
27 days ago